Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VistaGen to extend neurologic drug for Parkinson’s treatment
Treatment with AV-101 was found to increase the ‘firing rate’ and ‘burst firing’ activity of dopaminergic (DA) neurons by 27% and 61%, respectively. These are two key indicators
Treatment with AV-101 was found to increase the ‘firing rate’ and ‘burst firing’ activity of dopaminergic (DA) neurons by 27% and 61%, respectively. These are two key indicators
The National Institute of Neurological Disorders and Stroke granted Cambria a Phase I SBIR award to identify small molecule compounds that protect against cellular damage caused by the
During the experiments, 100% of the ferrets treated with VGX-3400 survived, while 100% of the control animals died. Vaccination with VGX-3400 generated potent neutralizing antibody and cell-mediated immune
These endocrine effects were associated with a significant increase in Fat Free Mass (FFM), and concomitant reduction in Fat Mass (FM) when measured by DEXA scan and bioelectrical
The multi-center studies evaluated the new once-daily formulation of Xibrom versus placebo in over 500 patients who underwent cataract surgery. The highly statistically significant findings demonstrated Xibrom QD
US-based Merck reached an agreement with the executive committee of the plaintiffs’ steering committee of the federal multidistrict Vioxx litigation as well as representatives of plaintiffs’ counsel in
Aureus Pharma’s target-family-based AurSCOPE knowledge databases contain quantitative biological activity data which has been mined from the scientific literature. By understanding existing structure activity relationships, and the overall
BioMarck Pharmaceuticals has licensed worldwide exclusive rights for this patent and related patents from North Carolina State University. The new patent provides broad protection for a series of
This study will evaluate analgesic efficacy, anti-inflammatory activity and safety of NSL-101 gel compared with the standard analgesic used in the scaling and root planing procedure for the
This tentative approval is the bioequivalent to Lamictal, a registered trademark of GlaxoSmithKline. Lamotrigine is indicated as adjunctive therapy for partial seizures (the generalized seizures of Lennox-Gastaut syndrome);